The NCCN's new resource educates patients on genetic testing for hereditary cancer risk, focusing on breast, ovarian, pancreatic, and prostate cancers. Advances in genetic technology, spurred by the ...
Free information from the National Comprehensive Cancer Network offers information on how and why to access genetic counseling and testing for multiple hereditary cancers “No other landscape in ...
Hosted on MSN
Study Finds Most Prostate Cancer Patients Following NCCN Guidelines Live Long, Healthy Lives
PLYMOUTH MEETING, PA — New research published in the July 2025 issue of JNCCN—Journal of the National Comprehensive Cancer Network offers encouraging news for men diagnosed with nonmetastatic prostate ...
Patients with nonmetastatic prostate cancer are more likely to die from other causes than from cancer when treated per guidelines. The 15-year cancer mortality risk is 5.5% for low-risk and 22% for ...
Today, the National Comprehensive Cancer Network ® (NCCN ®)-an alliance of leading cancer centers-published a new resource to inform people about the latest recommendations around hereditary and ...
Men treated for nonmetastatic prostate cancer under current guidelines are up to 6 times less likely to die from their cancer than from other causes, according to data from a Swedish cancer registry.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced the launch of its Decipher Prostate Metastatic Genomic Classifier ...
People with localized prostate cancer treated according to guidelines developed by an international panel of doctors are more likely to die of something other than the disease, new research shows. A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results